{"gene":"ERMN","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2006,"finding":"Ermin is a novel cytoskeletal molecule exclusively expressed by myelinating oligodendrocytes, localizing to the outer cytoplasmic lip of the myelin sheath and paranodal loops in mature nerves, and to F-actin-rich process tips ('Ermin spikes') in cultured oligodendrocytes. Ectopic expression of full-length Ermin, but not a mutant lacking the actin-binding domain, induced formation of numerous cell protrusions and pronounced morphological changes, demonstrating that its actin-binding domain is required for cytoskeletal rearrangement.","method":"Microarray expression profiling, immunohistochemistry/localization, ectopic expression with actin-binding domain deletion mutant in cultured cells","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (localization, domain-deletion mutagenesis, morphological readout) in a single foundational study, 95 citations","pmids":["16421295"],"is_preprint":false},{"year":2010,"finding":"Human Ermin (hErmin) regulates cytoskeletal rearrangement in oligodendrocytes via its actin-binding domain; full-length hErmin expressed in COS-7 cells promoted arborization and marked morphological change, while truncated mutants lacking the actin-binding domain did not.","method":"Ectopic expression of full-length and truncated hErmin constructs in COS-7 cells, morphological readout","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 — domain-deletion functional assay replicating findings from Brockschnieder 2006, single lab","pmids":["20934411"],"is_preprint":false},{"year":2020,"finding":"Ermin contributes to oligodendrocyte morphogenesis and myelin maintenance by associating with the myosin phosphatase Rho-interacting protein (Mprip/p116RIP) and inactivating RhoA, a GTPase controlling cytoskeletal rearrangement. Ermn-knockout mice exhibited aberrant myelin architecture (splitting, peeling, fiber breakdown), impaired motor coordination, and accelerated cuprizone-induced demyelination.","method":"Constitutive Ermn-knockout mouse generation, Co-IP/interaction studies with p116RIP, RhoA activity assays, behavioral testing, cuprizone demyelination model","journal":"Glia","confidence":"High","confidence_rationale":"Tier 2 — reciprocal interaction assay identifying p116RIP as binding partner, RhoA inactivation assay, in vivo KO with multiple defined phenotypic readouts","pmids":["32530539"],"is_preprint":false},{"year":2022,"finding":"Ermin is essential for myelin sheath integrity and normal saltatory conduction; loss of Ermin in mice caused de-compacted and fragmented myelin sheaths, slower nerve conduction, progressive neurological deficits, inflammatory activation (microgliosis, astrogliosis) in the corpus callosum, and increased susceptibility to immune-mediated demyelination. A rare inactivating ERMN mutation was identified in multiple sclerosis patients.","method":"Ermin-knockout mouse, RNA sequencing, electrophysiology (conduction velocity), immunohistochemistry for microgliosis/astrogliosis, experimental autoimmune demyelination challenge, human ERMN mutation screening","journal":"Brain pathology","confidence":"High","confidence_rationale":"Tier 2 — in vivo KO with multiple orthogonal readouts (electrophysiology, histology, transcriptomics, demyelination challenge), replicated in vivo phenotype from Wang 2020","pmids":["35285112"],"is_preprint":false},{"year":2019,"finding":"ERMN is the primary target of disrupted folate metabolism induced by sevoflurane anesthesia via epigenetic (DNA methylation) mechanisms. Restoration of ERMN expression via brain-targeted AAV-PHP.EB delivery rescued anesthesia-induced myelination deficits and cognitive impairment in mice, placing ERMN downstream of thymidylate synthase (TYMS) downregulation in folate metabolism.","method":"Transcriptome profiling and genome-wide DNA methylation analysis in rhesus macaque and mouse after sevoflurane exposure, AAV-mediated ERMN rescue in vivo, folic acid supplementation rescue, behavioral testing","journal":"EBioMedicine","confidence":"High","confidence_rationale":"Tier 2 — epistasis/rescue experiment placing ERMN downstream of folate-TYMS axis, multiple orthogonal methods including in vivo AAV rescue with functional readout","pmids":["31060905"],"is_preprint":false},{"year":2021,"finding":"Ermin-immunopositive oligodendrocytes are enriched in areas of active remyelination in both the cuprizone mouse model and MS lesions, with ermin proportion relative to Nogo-A increasing at remyelination onset, suggesting Ermin marks the remyelinating oligodendrocyte state.","method":"Immunohistochemistry and cell density quantification in cuprizone model and MS tissue, co-labeling with stage-specific oligodendrocyte markers (Nogo-A, O4, O1)","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 3 — localization with functional implication (remyelination marker), single study, no mechanistic intervention","pmids":["34437581"],"is_preprint":false},{"year":2016,"finding":"Rare genetic variants (meSNVs) at the ERMN locus cause hypomethylation and reduced ERMN expression in blood, and are significantly associated with autism spectrum disorder susceptibility; resequencing revealed a significant load of deleterious coding mutations in ERMN in ASD patients versus controls.","method":"Methylomic array (450K Illumina) on ASD patient blood DNA, blood RNAseq for cis-expression changes, case-control association study, targeted resequencing of ERMN","journal":"Translational psychiatry","confidence":"Medium","confidence_rationale":"Tier 3 — genetic and epigenetic association with functional expression consequence, single study without in vitro/in vivo mechanistic follow-up","pmids":["27404287"],"is_preprint":false}],"current_model":"ERMN encodes Ermin, an oligodendrocyte-specific actin-binding cytoskeletal protein that localizes to the outer cytoplasmic lip of the myelin sheath and paranodal loops; its actin-binding domain drives process formation and morphological remodeling in differentiating oligodendrocytes by associating with the myosin phosphatase Rho-interacting protein p116RIP and inactivating RhoA, and loss of Ermin in vivo causes myelin decompaction, slowed saltatory conduction, neuroinflammation, and hypersusceptibility to demyelination, while its expression is regulated downstream of folate metabolism via epigenetic mechanisms."},"narrative":{"teleology":[{"year":2006,"claim":"The discovery of Ermin as a novel myelinating-oligodendrocyte-specific molecule established a new cytoskeletal component of the myelin sheath, answering the question of what actin-binding proteins operate at the outer lip of myelin.","evidence":"Microarray profiling, immunohistochemistry on mature nerves, and ectopic expression of wild-type vs. actin-binding-domain-deleted Ermin in cultured cells","pmids":["16421295"],"confidence":"High","gaps":["Binding partners mediating Ermin's cytoskeletal effects were unknown","In vivo loss-of-function consequences were not tested","Upstream regulation of ERMN expression was uncharacterized"]},{"year":2010,"claim":"Replication with human Ermin confirmed that the actin-binding domain requirement for morphological remodeling is conserved, strengthening the case that this domain is the functional effector.","evidence":"Ectopic expression of full-length and truncated human Ermin in COS-7 cells with morphological readout","pmids":["20934411"],"confidence":"Medium","gaps":["Only a single heterologous cell system was used without oligodendrocyte context","Downstream signaling pathway linking actin-binding domain to cytoskeletal reorganization remained undefined"]},{"year":2016,"claim":"Genetic and epigenetic association of the ERMN locus with autism spectrum disorder raised the possibility that Ermin dysfunction contributes to neurodevelopmental conditions beyond demyelinating disease.","evidence":"Methylomic array, blood RNA-seq cis-expression analysis, and targeted resequencing in ASD case-control cohort","pmids":["27404287"],"confidence":"Medium","gaps":["No in vitro or in vivo mechanistic follow-up linking ERMN variants to oligodendrocyte or neural circuit dysfunction","Blood-based expression changes may not reflect CNS-specific effects","Association not independently replicated"]},{"year":2019,"claim":"Identification of ERMN as the principal downstream target of disrupted folate-TYMS metabolism resolved how anesthetic exposure impairs myelination and showed that ERMN transcription is epigenetically regulated via DNA methylation.","evidence":"Transcriptome and genome-wide methylation profiling in sevoflurane-exposed macaque and mouse, AAV-PHP.EB-mediated ERMN rescue and folic acid supplementation with behavioral readout","pmids":["31060905"],"confidence":"High","gaps":["The specific CpG sites and transcription factors governing ERMN methylation-dependent expression were not mapped","Whether folate-mediated ERMN regulation operates under physiological (non-anesthetic) conditions is unknown"]},{"year":2020,"claim":"Identification of p116RIP as an Ermin-binding partner and demonstration that Ermin inactivates RhoA provided the first mechanistic pathway linking Ermin to cytoskeletal signaling, while the knockout mouse revealed that Ermin is required for myelin structural integrity in vivo.","evidence":"Co-immunoprecipitation with p116RIP, RhoA activity assays, constitutive Ermn-KO mouse with behavioral, histological, and cuprizone-challenge phenotyping","pmids":["32530539"],"confidence":"High","gaps":["Whether Ermin acts solely through the p116RIP–RhoA axis or engages additional effectors is unknown","Temporal requirement of Ermin during initial myelination versus maintenance was not dissected"]},{"year":2021,"claim":"Enrichment of Ermin-positive oligodendrocytes in actively remyelinating lesions in both mouse and human tissue positioned Ermin as a marker of the remyelinating oligodendrocyte state, suggesting a functional role during myelin repair.","evidence":"Immunohistochemistry and cell density quantification in cuprizone model and MS lesions, co-labeling with stage-specific oligodendrocyte markers","pmids":["34437581"],"confidence":"Medium","gaps":["No interventional evidence that Ermin is functionally required for remyelination","Correlative marker data without lineage tracing or conditional knockout"]},{"year":2022,"claim":"Comprehensive phenotyping of Ermin-KO mice confirmed that Ermin is essential for myelin compaction and saltatory conduction, revealed progressive neuroinflammation as a consequence of myelin failure, and linked a rare inactivating human ERMN mutation to multiple sclerosis.","evidence":"Ermin-KO mouse with electrophysiology, RNA-seq, immunohistochemistry for gliosis, experimental autoimmune demyelination challenge, and human ERMN mutation screening in MS patients","pmids":["35285112"],"confidence":"High","gaps":["The identified human ERMN mutation was rare and causality for MS not formally established","Whether neuroinflammation is cell-autonomous or secondary to myelin debris was not resolved"]},{"year":null,"claim":"Key unresolved questions include the precise structural basis of the Ermin–actin and Ermin–p116RIP interactions, the temporal requirement for Ermin during developmental versus repair myelination, whether Ermin loss drives neuroinflammation cell-autonomously, and whether ERMN variants causally contribute to MS or ASD.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of Ermin or its complexes exists","Conditional (temporal/cell-type-specific) knockout studies have not been reported","Causal role of ERMN variants in human neurological disease is not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[0,1,2]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,2,3]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2]}],"complexes":[],"partners":["MPRIP"],"other_free_text":[]},"mechanistic_narrative":"ERMN encodes Ermin, an oligodendrocyte-specific actin-binding cytoskeletal protein that is essential for myelin sheath formation, compaction, and long-term maintenance in the central nervous system. Ermin localizes to the outer cytoplasmic lip of the myelin sheath and paranodal loops, where its actin-binding domain drives oligodendrocyte process extension and morphological remodeling; this cytoskeletal function is mediated through association with the myosin phosphatase Rho-interacting protein p116RIP and inactivation of RhoA [PMID:16421295, PMID:32530539]. Loss of Ermin in mice causes myelin decompaction and fragmentation, slowed nerve conduction, progressive neuroinflammation, motor deficits, and heightened susceptibility to both toxic and immune-mediated demyelination, and a rare inactivating ERMN mutation has been identified in multiple sclerosis patients [PMID:32530539, PMID:35285112]. ERMN expression is regulated downstream of folate metabolism via DNA methylation, and AAV-mediated restoration of ERMN rescues anesthesia-induced myelination deficits and cognitive impairment in mice [PMID:31060905]."},"prefetch_data":{"uniprot":{"accession":"Q8TAM6","full_name":"Ermin","aliases":["Juxtanodin","JN"],"length_aa":284,"mass_kda":32.8,"function":"Plays a role in cytoskeletal rearrangements during the late wrapping and/or compaction phases of myelinogenesis as well as in maintenance and stability of myelin sheath in the adult. May play an important role in late-stage oligodendroglia maturation, myelin/Ranvier node formation during CNS development, and in the maintenance and plasticity of related structures in the mature CNS (By similarity)","subcellular_location":"Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/Q8TAM6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ERMN","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ERMN","total_profiled":1310},"omim":[{"mim_id":"610072","title":"ERMIN; ERMN","url":"https://www.omim.org/entry/610072"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":596.2}],"url":"https://www.proteinatlas.org/search/ERMN"},"hgnc":{"alias_symbol":["JN","ERMIN"],"prev_symbol":["KIAA1189"]},"alphafold":{"accession":"Q8TAM6","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TAM6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TAM6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TAM6-F1-predicted_aligned_error_v6.png","plddt_mean":57.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ERMN","jax_strain_url":"https://www.jax.org/strain/search?query=ERMN"},"sequence":{"accession":"Q8TAM6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TAM6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TAM6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TAM6"}},"corpus_meta":[{"pmid":"38377995","id":"PMC_38377995","title":"XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.","date":"2024","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/38377995","citation_count":143,"is_preprint":false},{"pmid":"39510125","id":"PMC_39510125","title":"Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/39510125","citation_count":102,"is_preprint":false},{"pmid":"16421295","id":"PMC_16421295","title":"Ermin, a myelinating oligodendrocyte-specific protein that regulates cell morphology.","date":"2006","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16421295","citation_count":95,"is_preprint":false},{"pmid":"39024099","id":"PMC_39024099","title":"Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39024099","citation_count":67,"is_preprint":false},{"pmid":"15782132","id":"PMC_15782132","title":"Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15782132","citation_count":62,"is_preprint":false},{"pmid":"31060905","id":"PMC_31060905","title":"Disrupted folate metabolism with anesthesia leads to myelination deficits mediated by epigenetic regulation of ERMN.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31060905","citation_count":55,"is_preprint":false},{"pmid":"39259045","id":"PMC_39259045","title":"Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.","date":"2024","source":"Emerging microbes & infections","url":"https://pubmed.ncbi.nlm.nih.gov/39259045","citation_count":50,"is_preprint":false},{"pmid":"39379369","id":"PMC_39379369","title":"Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39379369","citation_count":47,"is_preprint":false},{"pmid":"39231977","id":"PMC_39231977","title":"Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39231977","citation_count":44,"is_preprint":false},{"pmid":"38302341","id":"PMC_38302341","title":"SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences.","date":"2024","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38302341","citation_count":40,"is_preprint":false},{"pmid":"29700636","id":"PMC_29700636","title":"Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).","date":"2018","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29700636","citation_count":40,"is_preprint":false},{"pmid":"38591890","id":"PMC_38591890","title":"Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.","date":"2024","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/38591890","citation_count":38,"is_preprint":false},{"pmid":"39446667","id":"PMC_39446667","title":"Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages - United States, May 2023-September 2024.","date":"2024","source":"MMWR. Morbidity and mortality weekly report","url":"https://pubmed.ncbi.nlm.nih.gov/39446667","citation_count":36,"is_preprint":false},{"pmid":"12218078","id":"PMC_12218078","title":"Establishment and characterization of a novel human desmoplastic small round cell tumor cell line, JN-DSRCT-1.","date":"2002","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12218078","citation_count":36,"is_preprint":false},{"pmid":"39013463","id":"PMC_39013463","title":"Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants.","date":"2024","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/39013463","citation_count":35,"is_preprint":false},{"pmid":"39081516","id":"PMC_39081516","title":"The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies.","date":"2024","source":"MedComm","url":"https://pubmed.ncbi.nlm.nih.gov/39081516","citation_count":32,"is_preprint":false},{"pmid":"27404287","id":"PMC_27404287","title":"Genetic and epigenetic methylation defects and implication of the ERMN gene in autism spectrum disorders.","date":"2016","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/27404287","citation_count":30,"is_preprint":false},{"pmid":"40136024","id":"PMC_40136024","title":"Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants.","date":"2025","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/40136024","citation_count":26,"is_preprint":false},{"pmid":"39339934","id":"PMC_39339934","title":"AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance.","date":"2024","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/39339934","citation_count":26,"is_preprint":false},{"pmid":"38257802","id":"PMC_38257802","title":"Timely Monitoring of SARS-CoV-2 RNA Fragments in Wastewater Shows the Emergence of JN.1 (BA.2.86.1.1, Clade 23I) in Berlin, Germany.","date":"2024","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/38257802","citation_count":24,"is_preprint":false},{"pmid":"39282390","id":"PMC_39282390","title":"Neutralization and Stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 Subvariants.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39282390","citation_count":23,"is_preprint":false},{"pmid":"39875585","id":"PMC_39875585","title":"T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots.","date":"2025","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39875585","citation_count":22,"is_preprint":false},{"pmid":"38812550","id":"PMC_38812550","title":"Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion.","date":"2024","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/38812550","citation_count":22,"is_preprint":false},{"pmid":"39375326","id":"PMC_39375326","title":"Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39375326","citation_count":20,"is_preprint":false},{"pmid":"38826376","id":"PMC_38826376","title":"Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38826376","citation_count":20,"is_preprint":false},{"pmid":"38428429","id":"PMC_38428429","title":"Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38428429","citation_count":18,"is_preprint":false},{"pmid":"20934411","id":"PMC_20934411","title":"Human Ermin (hErmin), a new oligodendrocyte-specific cytoskeletal protein related to epileptic seizure.","date":"2010","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/20934411","citation_count":18,"is_preprint":false},{"pmid":"39121195","id":"PMC_39121195","title":"SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines.","date":"2024","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39121195","citation_count":18,"is_preprint":false},{"pmid":"38583825","id":"PMC_38583825","title":"Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.","date":"2024","source":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","url":"https://pubmed.ncbi.nlm.nih.gov/38583825","citation_count":18,"is_preprint":false},{"pmid":"32530539","id":"PMC_32530539","title":"Ermin is a p116RIP -interacting protein promoting oligodendroglial differentiation and myelin maintenance.","date":"2020","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/32530539","citation_count":16,"is_preprint":false},{"pmid":"16772508","id":"PMC_16772508","title":"10.1093/jn/136.7.2090S.","date":"2006","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/16772508","citation_count":16,"is_preprint":false},{"pmid":"35285112","id":"PMC_35285112","title":"Ermin deficiency leads to compromised myelin, inflammatory milieu, and susceptibility to demyelinating insult.","date":"2022","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35285112","citation_count":16,"is_preprint":false},{"pmid":"38574739","id":"PMC_38574739","title":"Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.","date":"2024","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38574739","citation_count":16,"is_preprint":false},{"pmid":"38678055","id":"PMC_38678055","title":"Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1.","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38678055","citation_count":15,"is_preprint":false},{"pmid":"39896217","id":"PMC_39896217","title":"The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health.","date":"2025","source":"Therapeutic advances in infectious disease","url":"https://pubmed.ncbi.nlm.nih.gov/39896217","citation_count":15,"is_preprint":false},{"pmid":"29378189","id":"PMC_29378189","title":"JN-2, a C-X-C motif chemokine receptor 3 antagonist, ameliorates arthritis progression in an animal model.","date":"2018","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29378189","citation_count":15,"is_preprint":false},{"pmid":"38543838","id":"PMC_38543838","title":"Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.","date":"2024","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/38543838","citation_count":13,"is_preprint":false},{"pmid":"38622986","id":"PMC_38622986","title":"JN.1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)?","date":"2024","source":"Hormone molecular biology and clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38622986","citation_count":13,"is_preprint":false},{"pmid":"31123898","id":"PMC_31123898","title":"Down-regulation of ERMN expression in relapsing remitting multiple sclerosis.","date":"2019","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/31123898","citation_count":12,"is_preprint":false},{"pmid":"39738039","id":"PMC_39738039","title":"Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39738039","citation_count":11,"is_preprint":false},{"pmid":"39732637","id":"PMC_39732637","title":"Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.","date":"2024","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39732637","citation_count":10,"is_preprint":false},{"pmid":"38850530","id":"PMC_38850530","title":"Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38850530","citation_count":10,"is_preprint":false},{"pmid":"24879594","id":"PMC_24879594","title":"Over-expression of a proline specific aminopeptidase from Aspergillus oryzae JN-412 and its application in collagen degradation.","date":"2014","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/24879594","citation_count":10,"is_preprint":false},{"pmid":"39864525","id":"PMC_39864525","title":"Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.","date":"2025","source":"Antiviral research","url":"https://pubmed.ncbi.nlm.nih.gov/39864525","citation_count":10,"is_preprint":false},{"pmid":"38304689","id":"PMC_38304689","title":"Navigating Novel Uncertainties of COVID-19: The Rise of the JN.1 Variant.","date":"2024","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/38304689","citation_count":9,"is_preprint":false},{"pmid":"39562542","id":"PMC_39562542","title":"Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants.","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39562542","citation_count":8,"is_preprint":false},{"pmid":"39553825","id":"PMC_39553825","title":"Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants.","date":"2024","source":"Npj viruses","url":"https://pubmed.ncbi.nlm.nih.gov/39553825","citation_count":7,"is_preprint":false},{"pmid":"40056804","id":"PMC_40056804","title":"mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice.","date":"2025","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/40056804","citation_count":7,"is_preprint":false},{"pmid":"38646375","id":"PMC_38646375","title":"Appearance and Prevalence of JN.1 SARS-CoV-2 Variant in India and Its Clinical Profile in the State of Maharashtra.","date":"2024","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/38646375","citation_count":7,"is_preprint":false},{"pmid":"35964410","id":"PMC_35964410","title":"Investigation into the anti-airway inflammatory role of the PI3Kγ inhibitor JN-PK1: An in vitro and in vivo study.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35964410","citation_count":7,"is_preprint":false},{"pmid":"39080396","id":"PMC_39080396","title":"Emergence of SARS-CoV-2 omicron variant JN.1 in Tamil Nadu, India - Clinical characteristics and novel mutations.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39080396","citation_count":7,"is_preprint":false},{"pmid":"38677090","id":"PMC_38677090","title":"FLip mutations (L455F + F456L) in newly emerging VOI, JN.1: Its antibody and immune escape.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38677090","citation_count":7,"is_preprint":false},{"pmid":"39468971","id":"PMC_39468971","title":"XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.","date":"2024","source":"Alimentary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/39468971","citation_count":7,"is_preprint":false},{"pmid":"40298448","id":"PMC_40298448","title":"Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3.","date":"2025","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/40298448","citation_count":6,"is_preprint":false},{"pmid":"34349621","id":"PMC_34349621","title":"Expression Analysis of Ermin and Listerin E3 Ubiquitin Protein Ligase 1 Genes in Autistic Patients.","date":"2021","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34349621","citation_count":6,"is_preprint":false},{"pmid":"39026832","id":"PMC_39026832","title":"Atomistic Prediction of Structures, Conformational Ensembles and Binding Energetics for the SARS-CoV-2 Spike JN.1, KP.2 and KP.3 Variants Using AlphaFold2 and Molecular Dynamics Simulations: Mutational Profiling and Binding Free Energy Analysis Reveal Epistatic Hotspots of the ACE2 Affinity and Immune Escape.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39026832","citation_count":6,"is_preprint":false},{"pmid":"40985731","id":"PMC_40985731","title":"Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2.","date":"2025","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/40985731","citation_count":5,"is_preprint":false},{"pmid":"40035925","id":"PMC_40035925","title":"A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants.","date":"2025","source":"Molecular biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/40035925","citation_count":5,"is_preprint":false},{"pmid":"34676516","id":"PMC_34676516","title":"Expression Analysis of Ermin and Listerin E3 Ubiquitin Protein Ligase 1 Genes in the Periphery of Patients with Schizophrenia.","date":"2021","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/34676516","citation_count":5,"is_preprint":false},{"pmid":"39908098","id":"PMC_39908098","title":"Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/39908098","citation_count":5,"is_preprint":false},{"pmid":"40000611","id":"PMC_40000611","title":"A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants.","date":"2025","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/40000611","citation_count":4,"is_preprint":false},{"pmid":"34437581","id":"PMC_34437581","title":"A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34437581","citation_count":4,"is_preprint":false},{"pmid":"38779718","id":"PMC_38779718","title":"SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.","date":"2024","source":"Emerging microbes & infections","url":"https://pubmed.ncbi.nlm.nih.gov/38779718","citation_count":4,"is_preprint":false},{"pmid":"15725679","id":"PMC_15725679","title":"Pattern of compensatory expression of voltage-dependent Ca2+ channel alpha1 and beta subunits in brain of N-type Ca2+ channel alpha1B subunit gene-deficient mice with a CBA/JN genetic background.","date":"2005","source":"Experimental animals","url":"https://pubmed.ncbi.nlm.nih.gov/15725679","citation_count":4,"is_preprint":false},{"pmid":"40639176","id":"PMC_40639176","title":"Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC.","date":"2025","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/40639176","citation_count":3,"is_preprint":false},{"pmid":"41381428","id":"PMC_41381428","title":"Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41381428","citation_count":3,"is_preprint":false},{"pmid":"39018495","id":"PMC_39018495","title":"Protective Non-neutralizing anti-N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence.","date":"2024","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/39018495","citation_count":3,"is_preprint":false},{"pmid":"39776396","id":"PMC_39776396","title":"Evaluating the Anti-inflammatory Potential of JN-KI3: The Therapeutic Role of PI3Kγ-Selective Inhibitors in Asthma Treatment.","date":"2025","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39776396","citation_count":3,"is_preprint":false},{"pmid":"41012604","id":"PMC_41012604","title":"Pathogenicity of SARS-CoV-2 Omicron Subvariants JN.1, KP.2, and EG.5.1 in K18-hACE2 Transgenic Mice.","date":"2025","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/41012604","citation_count":3,"is_preprint":false},{"pmid":"39471972","id":"PMC_39471972","title":"Integrated all-atom and coarse-grained simulations uncover structural, dynamics and energetic shifts in SARS-CoV-2 JN.1 and BA.2.86 variants.","date":"2024","source":"Acta tropica","url":"https://pubmed.ncbi.nlm.nih.gov/39471972","citation_count":3,"is_preprint":false},{"pmid":"16774125","id":"PMC_16774125","title":"Enhanced expression of Ca2+ channel alpha1A and beta4 subunits and phosphorylated tyrosine hydroxylase in the adrenal gland of N-type Ca2+ channel alpha1B subunit-deficient mice with a CBA/JN genetic background.","date":"2006","source":"Comparative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16774125","citation_count":3,"is_preprint":false},{"pmid":"41350251","id":"PMC_41350251","title":"Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41350251","citation_count":2,"is_preprint":false},{"pmid":"40022017","id":"PMC_40022017","title":"JN.1 variants circulating in Italy from October 2023 to April 2024: genetic diversity and immune recognition.","date":"2025","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40022017","citation_count":2,"is_preprint":false},{"pmid":"39772110","id":"PMC_39772110","title":"T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects.","date":"2024","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/39772110","citation_count":2,"is_preprint":false},{"pmid":"40042313","id":"PMC_40042313","title":"XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies.","date":"2025","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/40042313","citation_count":2,"is_preprint":false},{"pmid":"38717854","id":"PMC_38717854","title":"Unveiling the emergence of SARS-CoV-2 JN.1 sub-variant: Insights from the first cases at Charles Nicolle Hospital, Tunisia.","date":"2024","source":"Acta microbiologica et immunologica Hungarica","url":"https://pubmed.ncbi.nlm.nih.gov/38717854","citation_count":2,"is_preprint":false},{"pmid":"40605422","id":"PMC_40605422","title":"Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4+ T-Cell Activity.","date":"2025","source":"Transplant infectious disease : an official journal of the Transplantation Society","url":"https://pubmed.ncbi.nlm.nih.gov/40605422","citation_count":2,"is_preprint":false},{"pmid":"39591144","id":"PMC_39591144","title":"STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.","date":"2024","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/39591144","citation_count":2,"is_preprint":false},{"pmid":"39221683","id":"PMC_39221683","title":"SARS-CoV-2 JN.1 variant: a short review.","date":"2024","source":"Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace","url":"https://pubmed.ncbi.nlm.nih.gov/39221683","citation_count":1,"is_preprint":false},{"pmid":"40482468","id":"PMC_40482468","title":"An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant.","date":"2025","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/40482468","citation_count":1,"is_preprint":false},{"pmid":"39108735","id":"PMC_39108735","title":"Immunogen characterization reveals an intrinsic hindrance in eliciting neutralizing antibodies against JN.1 variant.","date":"2024","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/39108735","citation_count":1,"is_preprint":false},{"pmid":"39772248","id":"PMC_39772248","title":"Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients.","date":"2024","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/39772248","citation_count":1,"is_preprint":false},{"pmid":"38699322","id":"PMC_38699322","title":"Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India - Clinical Characteristics and Novel Mutations.","date":"2024","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38699322","citation_count":1,"is_preprint":false},{"pmid":"38559216","id":"PMC_38559216","title":"Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38559216","citation_count":1,"is_preprint":false},{"pmid":"41012630","id":"PMC_41012630","title":"Long-Term Genomic Surveillance and Immune Escape of SARS-CoV-2 in the Republic of Korea, with a Focus on JN.1-Derived Variants.","date":"2025","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/41012630","citation_count":1,"is_preprint":false},{"pmid":"39765094","id":"PMC_39765094","title":"Macromolecular interaction mechanism of the bacteriocin EntDD14 with the receptor binding domain (RBD) for the inhibition of SARS-CoV-2 and the JN.1 variant: Biomedical study based on elastic networks, stochastic Markov models, and macromolecular volumetric analysis.","date":"2024","source":"Biophysical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39765094","citation_count":1,"is_preprint":false},{"pmid":"41815056","id":"PMC_41815056","title":"Strain-specific anti-RBD IgG antibody titers against the WT, XBB.1.5, JN.1, and KP.3 strains consistently correlate with neutralizing activity following SARS-CoV-2 XBB.1.5-adapted mRNA vaccination.","date":"2025","source":"Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/41815056","citation_count":0,"is_preprint":false},{"pmid":"40599320","id":"PMC_40599320","title":"Enhanced reverse zoonotic potential and immune evasion by omicron JN.1 variant.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/40599320","citation_count":0,"is_preprint":false},{"pmid":"40556423","id":"PMC_40556423","title":"TMEM106B Supports Viral Entry and Syncytia Formation Mediated by the Spike Proteins From Omicron BA.2.86 and JN.1.","date":"2025","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/40556423","citation_count":0,"is_preprint":false},{"pmid":"39205166","id":"PMC_39205166","title":"Semi-Covariance Coefficient Analysis of Spike Proteins from SARS-CoV-2 and Its Variants Omicron, BA.5, EG.5, and JN.1 for Viral Infectivity, Virulence and Immune Escape.","date":"2024","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/39205166","citation_count":0,"is_preprint":false},{"pmid":"38746414","id":"PMC_38746414","title":"Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variants.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38746414","citation_count":0,"is_preprint":false},{"pmid":"38939989","id":"PMC_38939989","title":"Exploring New COVID-19 Incertitude: JN.1 Variant- JN.1: The Queer Bird among Omicron Sublineages.","date":"2025","source":"Infectious disorders drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/38939989","citation_count":0,"is_preprint":false},{"pmid":"41832695","id":"PMC_41832695","title":"The JN.1 Variant: Emergence and Global Spread.","date":"2026","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/41832695","citation_count":0,"is_preprint":false},{"pmid":"39263330","id":"PMC_39263330","title":"Rapid identification of SARS CoV-2 omicron sub-variant JN.1 (BA.2.86.1.1) with mass spectrometry.","date":"2024","source":"Journal of mass spectrometry and advances in the clinical lab","url":"https://pubmed.ncbi.nlm.nih.gov/39263330","citation_count":0,"is_preprint":false},{"pmid":"40408899","id":"PMC_40408899","title":"Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains.","date":"2025","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/40408899","citation_count":0,"is_preprint":false},{"pmid":"40575649","id":"PMC_40575649","title":"Alpha to JN.1 variants: SARS-CoV-2 genomic analysis unfolding its various lineages/sublineages evolved in Chhattisgarh, India from 2020 to 2024.","date":"2025","source":"World journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/40575649","citation_count":0,"is_preprint":false},{"pmid":"41316988","id":"PMC_41316988","title":"Antigenic drift in SARS-CoV-2: diminished vaccine protection in pediatric populations against Omicron and its JN.1 subvariant.","date":"2025","source":"Expert review of vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/41316988","citation_count":0,"is_preprint":false},{"pmid":"41874023","id":"PMC_41874023","title":"Discovery of Anti-SARS-CoV-2 XBB.1.5 and JN.1 Variant-Specific Monoclonal Single-Domain Antibodies from a Synthetic Library.","date":"2026","source":"Antibodies (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41874023","citation_count":0,"is_preprint":false},{"pmid":"41012675","id":"PMC_41012675","title":"Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay.","date":"2025","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/41012675","citation_count":0,"is_preprint":false},{"pmid":"40570671","id":"PMC_40570671","title":"SARS-CoV-2 sublineages recovered from southern Brazilian cases during Omicron wave in 2023, early introduction of JN.1.","date":"2025","source":"The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40570671","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55080,"output_tokens":1933,"usd":0.097117},"stage2":{"model":"claude-opus-4-6","input_tokens":5185,"output_tokens":2100,"usd":0.117638},"total_usd":0.214755,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"Ermin is a novel cytoskeletal molecule exclusively expressed by myelinating oligodendrocytes, localizing to the outer cytoplasmic lip of the myelin sheath and paranodal loops in mature nerves, and to F-actin-rich process tips ('Ermin spikes') in cultured oligodendrocytes. Ectopic expression of full-length Ermin, but not a mutant lacking the actin-binding domain, induced formation of numerous cell protrusions and pronounced morphological changes, demonstrating that its actin-binding domain is required for cytoskeletal rearrangement.\",\n      \"method\": \"Microarray expression profiling, immunohistochemistry/localization, ectopic expression with actin-binding domain deletion mutant in cultured cells\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (localization, domain-deletion mutagenesis, morphological readout) in a single foundational study, 95 citations\",\n      \"pmids\": [\"16421295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Human Ermin (hErmin) regulates cytoskeletal rearrangement in oligodendrocytes via its actin-binding domain; full-length hErmin expressed in COS-7 cells promoted arborization and marked morphological change, while truncated mutants lacking the actin-binding domain did not.\",\n      \"method\": \"Ectopic expression of full-length and truncated hErmin constructs in COS-7 cells, morphological readout\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain-deletion functional assay replicating findings from Brockschnieder 2006, single lab\",\n      \"pmids\": [\"20934411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Ermin contributes to oligodendrocyte morphogenesis and myelin maintenance by associating with the myosin phosphatase Rho-interacting protein (Mprip/p116RIP) and inactivating RhoA, a GTPase controlling cytoskeletal rearrangement. Ermn-knockout mice exhibited aberrant myelin architecture (splitting, peeling, fiber breakdown), impaired motor coordination, and accelerated cuprizone-induced demyelination.\",\n      \"method\": \"Constitutive Ermn-knockout mouse generation, Co-IP/interaction studies with p116RIP, RhoA activity assays, behavioral testing, cuprizone demyelination model\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interaction assay identifying p116RIP as binding partner, RhoA inactivation assay, in vivo KO with multiple defined phenotypic readouts\",\n      \"pmids\": [\"32530539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Ermin is essential for myelin sheath integrity and normal saltatory conduction; loss of Ermin in mice caused de-compacted and fragmented myelin sheaths, slower nerve conduction, progressive neurological deficits, inflammatory activation (microgliosis, astrogliosis) in the corpus callosum, and increased susceptibility to immune-mediated demyelination. A rare inactivating ERMN mutation was identified in multiple sclerosis patients.\",\n      \"method\": \"Ermin-knockout mouse, RNA sequencing, electrophysiology (conduction velocity), immunohistochemistry for microgliosis/astrogliosis, experimental autoimmune demyelination challenge, human ERMN mutation screening\",\n      \"journal\": \"Brain pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO with multiple orthogonal readouts (electrophysiology, histology, transcriptomics, demyelination challenge), replicated in vivo phenotype from Wang 2020\",\n      \"pmids\": [\"35285112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERMN is the primary target of disrupted folate metabolism induced by sevoflurane anesthesia via epigenetic (DNA methylation) mechanisms. Restoration of ERMN expression via brain-targeted AAV-PHP.EB delivery rescued anesthesia-induced myelination deficits and cognitive impairment in mice, placing ERMN downstream of thymidylate synthase (TYMS) downregulation in folate metabolism.\",\n      \"method\": \"Transcriptome profiling and genome-wide DNA methylation analysis in rhesus macaque and mouse after sevoflurane exposure, AAV-mediated ERMN rescue in vivo, folic acid supplementation rescue, behavioral testing\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis/rescue experiment placing ERMN downstream of folate-TYMS axis, multiple orthogonal methods including in vivo AAV rescue with functional readout\",\n      \"pmids\": [\"31060905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Ermin-immunopositive oligodendrocytes are enriched in areas of active remyelination in both the cuprizone mouse model and MS lesions, with ermin proportion relative to Nogo-A increasing at remyelination onset, suggesting Ermin marks the remyelinating oligodendrocyte state.\",\n      \"method\": \"Immunohistochemistry and cell density quantification in cuprizone model and MS tissue, co-labeling with stage-specific oligodendrocyte markers (Nogo-A, O4, O1)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization with functional implication (remyelination marker), single study, no mechanistic intervention\",\n      \"pmids\": [\"34437581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Rare genetic variants (meSNVs) at the ERMN locus cause hypomethylation and reduced ERMN expression in blood, and are significantly associated with autism spectrum disorder susceptibility; resequencing revealed a significant load of deleterious coding mutations in ERMN in ASD patients versus controls.\",\n      \"method\": \"Methylomic array (450K Illumina) on ASD patient blood DNA, blood RNAseq for cis-expression changes, case-control association study, targeted resequencing of ERMN\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genetic and epigenetic association with functional expression consequence, single study without in vitro/in vivo mechanistic follow-up\",\n      \"pmids\": [\"27404287\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ERMN encodes Ermin, an oligodendrocyte-specific actin-binding cytoskeletal protein that localizes to the outer cytoplasmic lip of the myelin sheath and paranodal loops; its actin-binding domain drives process formation and morphological remodeling in differentiating oligodendrocytes by associating with the myosin phosphatase Rho-interacting protein p116RIP and inactivating RhoA, and loss of Ermin in vivo causes myelin decompaction, slowed saltatory conduction, neuroinflammation, and hypersusceptibility to demyelination, while its expression is regulated downstream of folate metabolism via epigenetic mechanisms.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ERMN encodes Ermin, an oligodendrocyte-specific actin-binding cytoskeletal protein that is essential for myelin sheath formation, compaction, and long-term maintenance in the central nervous system. Ermin localizes to the outer cytoplasmic lip of the myelin sheath and paranodal loops, where its actin-binding domain drives oligodendrocyte process extension and morphological remodeling; this cytoskeletal function is mediated through association with the myosin phosphatase Rho-interacting protein p116RIP and inactivation of RhoA [PMID:16421295, PMID:32530539]. Loss of Ermin in mice causes myelin decompaction and fragmentation, slowed nerve conduction, progressive neuroinflammation, motor deficits, and heightened susceptibility to both toxic and immune-mediated demyelination, and a rare inactivating ERMN mutation has been identified in multiple sclerosis patients [PMID:32530539, PMID:35285112]. ERMN expression is regulated downstream of folate metabolism via DNA methylation, and AAV-mediated restoration of ERMN rescues anesthesia-induced myelination deficits and cognitive impairment in mice [PMID:31060905].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"The discovery of Ermin as a novel myelinating-oligodendrocyte-specific molecule established a new cytoskeletal component of the myelin sheath, answering the question of what actin-binding proteins operate at the outer lip of myelin.\",\n      \"evidence\": \"Microarray profiling, immunohistochemistry on mature nerves, and ectopic expression of wild-type vs. actin-binding-domain-deleted Ermin in cultured cells\",\n      \"pmids\": [\"16421295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Binding partners mediating Ermin's cytoskeletal effects were unknown\",\n        \"In vivo loss-of-function consequences were not tested\",\n        \"Upstream regulation of ERMN expression was uncharacterized\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Replication with human Ermin confirmed that the actin-binding domain requirement for morphological remodeling is conserved, strengthening the case that this domain is the functional effector.\",\n      \"evidence\": \"Ectopic expression of full-length and truncated human Ermin in COS-7 cells with morphological readout\",\n      \"pmids\": [\"20934411\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Only a single heterologous cell system was used without oligodendrocyte context\",\n        \"Downstream signaling pathway linking actin-binding domain to cytoskeletal reorganization remained undefined\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Genetic and epigenetic association of the ERMN locus with autism spectrum disorder raised the possibility that Ermin dysfunction contributes to neurodevelopmental conditions beyond demyelinating disease.\",\n      \"evidence\": \"Methylomic array, blood RNA-seq cis-expression analysis, and targeted resequencing in ASD case-control cohort\",\n      \"pmids\": [\"27404287\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No in vitro or in vivo mechanistic follow-up linking ERMN variants to oligodendrocyte or neural circuit dysfunction\",\n        \"Blood-based expression changes may not reflect CNS-specific effects\",\n        \"Association not independently replicated\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of ERMN as the principal downstream target of disrupted folate-TYMS metabolism resolved how anesthetic exposure impairs myelination and showed that ERMN transcription is epigenetically regulated via DNA methylation.\",\n      \"evidence\": \"Transcriptome and genome-wide methylation profiling in sevoflurane-exposed macaque and mouse, AAV-PHP.EB-mediated ERMN rescue and folic acid supplementation with behavioral readout\",\n      \"pmids\": [\"31060905\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The specific CpG sites and transcription factors governing ERMN methylation-dependent expression were not mapped\",\n        \"Whether folate-mediated ERMN regulation operates under physiological (non-anesthetic) conditions is unknown\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of p116RIP as an Ermin-binding partner and demonstration that Ermin inactivates RhoA provided the first mechanistic pathway linking Ermin to cytoskeletal signaling, while the knockout mouse revealed that Ermin is required for myelin structural integrity in vivo.\",\n      \"evidence\": \"Co-immunoprecipitation with p116RIP, RhoA activity assays, constitutive Ermn-KO mouse with behavioral, histological, and cuprizone-challenge phenotyping\",\n      \"pmids\": [\"32530539\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether Ermin acts solely through the p116RIP–RhoA axis or engages additional effectors is unknown\",\n        \"Temporal requirement of Ermin during initial myelination versus maintenance was not dissected\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Enrichment of Ermin-positive oligodendrocytes in actively remyelinating lesions in both mouse and human tissue positioned Ermin as a marker of the remyelinating oligodendrocyte state, suggesting a functional role during myelin repair.\",\n      \"evidence\": \"Immunohistochemistry and cell density quantification in cuprizone model and MS lesions, co-labeling with stage-specific oligodendrocyte markers\",\n      \"pmids\": [\"34437581\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No interventional evidence that Ermin is functionally required for remyelination\",\n        \"Correlative marker data without lineage tracing or conditional knockout\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Comprehensive phenotyping of Ermin-KO mice confirmed that Ermin is essential for myelin compaction and saltatory conduction, revealed progressive neuroinflammation as a consequence of myelin failure, and linked a rare inactivating human ERMN mutation to multiple sclerosis.\",\n      \"evidence\": \"Ermin-KO mouse with electrophysiology, RNA-seq, immunohistochemistry for gliosis, experimental autoimmune demyelination challenge, and human ERMN mutation screening in MS patients\",\n      \"pmids\": [\"35285112\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The identified human ERMN mutation was rare and causality for MS not formally established\",\n        \"Whether neuroinflammation is cell-autonomous or secondary to myelin debris was not resolved\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the precise structural basis of the Ermin–actin and Ermin–p116RIP interactions, the temporal requirement for Ermin during developmental versus repair myelination, whether Ermin loss drives neuroinflammation cell-autonomously, and whether ERMN variants causally contribute to MS or ASD.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural model of Ermin or its complexes exists\",\n        \"Conditional (temporal/cell-type-specific) knockout studies have not been reported\",\n        \"Causal role of ERMN variants in human neurological disease is not established\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 2, 3]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"MPRIP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}